Form 4: Xilio Therapeutics CFO Granted Stock Options

Christopher James Frankenfield, CFO of Xilio Therapeutics, was granted stock options to purchase 75,000 shares of common stock.

Summary

• Christopher James Frankenfield, the Chief Financial Officer of Xilio Therapeutics, Inc. (XLO), was granted stock options on April 15, 2025.
• The options allow him to purchase 75,000 shares of XLO's common stock at an exercise price of $0.712 per share.
• The options vest in equal monthly installments starting May 1, 2025, and continuing through April 1, 2029.
• The options expire on April 14, 2035.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. It's a standard practice, so neither particularly positive nor negative.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Xilio Therapeutics.
• Comparable companies such as Arcus Biosciences, Surface Oncology, and Compass Therapeutics also utilize stock options as part of their executive compensation plans.
• The size of the grant (75,000 shares) would need to be compared to the total outstanding shares and the typical grant size for CFOs at similar-stage biotech companies to assess its relative significance.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the CFO's interests with the company's long-term success.
• Employees may see this as a sign of stability and investment in the leadership team.

Key Dates

Keywords

stock options, Xilio Therapeutics, CFO, Frankenfield, equity compensation, Form 4